Oral formulation of nanocrystals: Interview with Demo Case partner MyBiotech
MyBiotech developed a fast-acting oral formulation of NSAID nanocrystals without food effect. Free base formulations of NSAIDs have low COGs but slow onset of action and are associated with GI-tract adverse events. Previous attempts from multiple parties to develop faster acting formulations resulted in increased COGs and couldn’t eliminate performance difference between fed and fasted state to date.
A fast-acting oral formulation of Ibuprofen nanocrystals without food effect produced with a process overcoming manufacturing challenges of scalability, stability and batch-to-batch variations for nanocrystals exceeds the expectations. Clinical test material of this oral nanoformulation will be produced under GMP conditions ready for clinical trials.
Watch our interview with MyBiotech’s Chief Scientific Officer Dr. Emre Türeli to learn about his experience accessing services from PHOENIX-OITB partners, guided by the PHOENIX SEP (single-entry-point).
